Thursday 16 October, 2025
Objectives: Although a higher plasma exposure is observed after oral than inhaled dosing of salbutamol (2 mg and 400 µg, respectively),…
Read morePoster: Drug/Disease Modelling - Absorption & PBPK
Whole-body physiology pharmacokinetic modeling of flip-flop behavior of oral oxycodone solution in pediatric patients 5-16 years old
Thursday 16 October, 2025
Objectives: The semi-synthetic opioid analgesic oxycodone has in some trials exhibited flip-flop pharmacokinetics when administered as an immediate-release formulation [1]….
Read moreAsymptotic Analysis on a TMDD model: Control of the process
Thursday 16 October, 2025
Objectives: A detailed analysis of a multi-scale pharmacokinetic-pharmacodynamic (PKPD), one compartment, target mediated drug disposition model (TMDD) is performed. This…
Read morePopulation Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect
Thursday 16 October, 2025
Objectives: Despite its long term use as an established diuretic, the anti-hypertensive effect of furosemide has not been well characterized….
Read moreA semi-PBPK model to describe the mechanism based drug-drug interaction between S-ketamine and ticlopidine in healthy human volunteers.
Thursday 16 October, 2025
Objectives: Low dose S-Ketamine has been shown to be useful as an adjuvant in pain medicine (1). However oral S-ketamine…
Read morePB-QSP model of type 2 diabetes for individualized prediction of treatment combination outcomes with metformin, DPP4i, and SGLT2i.
Thursday 16 October, 2025
Objectives: Type 2 Diabetes Mellitus (T2DM) is a complex disease that results in the dysregulation of glucose control and elevated…
Read moreMechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework
Thursday 16 October, 2025
Introduction: The subcutaneous (SC) route of administration is frequently used to deliver therapeutic proteins (TPs). However, the systemic bioavailability of…
Read moreA platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework
Thursday 16 October, 2025
Background: Mechanistic models for subcutaneous (SC) administration in combination with physiologically-based pharmacokinetic (PBPK) modelling are valuable in that they allow…
Read morePhysiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor
Thursday 16 October, 2025
Objectives: Physiologically-based (PB) systems pharmacology models of glucose homeostasis allow insight into diseases such as type 2 diabetes mellitus (T2DM)….
Read moreA Physiologically-based Quantitative Systems Pharmacology model of the incretin hormones GLP-1 and GIP
Thursday 16 October, 2025
Objectives: The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are crucial for the regulation of postprandial glucose….
Read more